Calithera Biosciences

Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on discovering and developing small molecule drugs that target novel and critical metabolic pathways in tumor and cancer-fighting immune cells. It offers programs such as Pipeline, Glutaminase Inhibitor, and Arginase Inhibitor. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Calithera Biosciences, Inc. is a clinical stage precision oncology biopharmaceutical company, which engages in developing targeted therapies to redefine treatment for biomarker-specific patient populations. It also focuses on researching small molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic. The company was founded by James A. Wells and Susan M. Molineaux on March 9, 2010 and is headquartered in South San Francisco, CA.

Calithera Biosciences' (CALA) CEO Susan Molineaux on Q2 2021 Results - Earnings Call Transcript

-- Cash, Cash Equivalents and Investments Totaled $92.2 million as of June 30, 2021 -- -- Conference Call and Webcast Scheduled for 2:00 p.m. PT on August 5, 2021--

Calithera Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights

Calithera is guiding for the market to expect what we believe will be a key data read-out from its ongoing CB-280 study involving Cystic Fibrosis. We anticipate full data set to read out in early October at the North American Cystic Fibrosis Conference.

The Upcoming Calithera Cystic Fibrosis Data Could Be Significant

SOUTH SAN FRANCISCO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a fully-integrated clinical-stage biotechnology company focused on discovering and developing novel, small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the Company's second quarter 2021 financial results will be released on Thursday, August 5, 2021. Company management will host a conference call on Thursday, August 5, 2021 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.

Calithera Biosciences to Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021

Investors need to pay close attention to Calithera Biosciences (CALA) stock based on the movements in the options market lately.

Implied Volatility Surging for Calithera Biosciences (CALA) Stock Options

SOUTH SAN FRANCISCO, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, today shared final results from the Phase 2 CANTATA study evaluating the company's glutaminase inhibitor telaglenastat (CB-839). The findings were highlighted in an oral presentation at the virtual American Society of Clinical Oncology (ASCO) 2021 Annual Meeting.

Final Data from Calithera Biosciences' Phase 2 CANTATA Study in Renal Cell Carcinoma Presented at 2021 ASCO Annual Meeting

SHANGHAI and SOUTH SAN FRANCISCO, Calif., May 17, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, and Calithera Biosciences, Inc. ("Calithera", Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced an exclusive, worldwide license agreement for the development and commercialization of CB-708 (ATG-037), Calithera's small molecule inhibitor of CD73.

Antengene and Calithera Biosciences Enter into Worldwide Exclusive License Agreement to Develop and Commercialize CD73 Inhibitor CB-708 (ATG-037)

Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q1 2021 Results - Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the Company's first quarter 2021 financial results will be released on Thursday, May 6, 2021. Company management will host a conference call on Thursday, May 6, 2021 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.

Calithera Biosciences to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021

SOUTH SAN FRANCISCO, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that final results from the CANTATA clinical study will be shared in an oral presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting taking place virtually June 4-8, 2021.

Results from Calithera Biosciences' CANTATA Study to Be Presented at 2021 ASCO Annual Meeting

Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q4 2020 Results - Earnings Call Transcript

--Calithera to Provide Corporate Update via Conference Call and Webcast at 2:00 p.m. PT on March 16, 2021-- SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, announced today its financial results for the fourth quarter ended December 31, 2020. As of December 31, 2020, cash, cash equivalents and investments totaled $115.2 million.

Calithera Biosciences Reports Fourth Quarter 2020 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., March 12, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the Company's fourth quarter 2020 financial results will be released on Tuesday, March 16, 2021. Company management will host a conference call on Tuesday, March 16, 2021 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.

UPDATE – Calithera Biosciences to Report Fourth Quarter 2020 Financial Results on Tuesday, March 16, 2021

SOUTH SAN FRANCISCO, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the Company's fourth quarter 2020 financial results will be released on Tuesday, March 16, 2021. Company management will host a conference call on Tuesday, March 16, 2021 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.

Calithera Biosciences to Report Fourth Quarter 2021 Financial Results on Tuesday, March 16, 2021

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that preliminary safety and efficacy data from a trial evaluating the arginase inhibitor INCB001158, which is being developed by Incyte Pharmaceuticals, will be presented in a virtual poster session at the American Society of Clinical Oncology (ASCO) 2021 Gastrointestinal Cancers Virtual Symposium taking place January 15-17, 2021.

INCB001158 Biliary Tract Cancer Data to be Presented at 2021 Virtual ASCO Gastrointestinal Cancers Symposium

Calithera (CALA) tanks as CANTATA study on its lead pipeline candidate, telaglenastat, did not achieve its primary goal for RCC.

Calithera (CALA) Plunges as CANTANA Study on Telaglenastat Fails

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that Susan Molineaux, Ph.D., the company's founder, president and chief executive officer, will present at the H.C. Wainwright VIRTUAL BioConnect Conference. The presentation will be available on January 11, 2021, and a webcast for replay for up to 30 days at www.calithera.com in the Investor Relations section.

Calithera to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

Bionano Genomics

Calithera Biosciences (NASDAQ: CALA) shares are trading lower after the company announced that its CANTATA study of Telaglenastat in Renal Cell Carcinoma did not achieve its primary endpoint. The company also announced a reduction in workforce by roughly 35%.

Why Calithera, BioNano Genomics And More Are Moving Today

The company reported negative results from a clinical trial.

Why Calithera Biosciences Stock Is Plunging Today

-- Company will continue to advance telaglenastat KEAPSAKE trial in non-small cell lung cancer, arginase inhibitor CB-280 trial in cystic fibrosis and emerging pipeline

Calithera Biosciences Reports CANTATA Study of Telaglenastat in Renal Cell Carcinoma Did Not Achieve Primary Endpoint

SOUTH SAN FRANCISCO, Calif., Dec. 31, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the compensation committee of the company's board of directors granted one new employee a non-qualified stock option to purchase an aggregate of 50,000 shares of Calithera's common stock, at a per share exercise price of $4.91, the closing trading price on December 31, 2020. One-fourth of the option vests in December 2021, and the balance of the option vests in a series of thirty-six successive equal monthly installments thereafter and was granted pursuant to the Calithera Biosciences, Inc. 2018 Inducement Plan, or Inducement Plan, which was approved by Calithera's board of directors in January 2018 in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option also has a ten-year term and is subject to the terms and conditions of the Inducement Plan and the stock option agreement pursuant to which the option was granted.

Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Investors need to pay close attention to Calithera (CALA) stock based on the movements in the options market lately.

Do Options Traders Know Something About Calithera (CALA) Stock We Don't?

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the compensation committee of the company's board of directors granted three new employees a non-qualified stock option to purchase an aggregate of 53,000 shares of Calithera's common stock, at a per share exercise price of $4.91, the closing trading price on November 30, 2020. One-fourth of the options vest in November 2021, and the balance of the options vest in a series of thirty-six successive equal monthly installments thereafter and were granted pursuant to the Calithera Biosciences, Inc. 2018 Inducement Plan, or Inducement Plan, which was approved by Calithera's board of directors in January 2018 in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options also have a ten-year term and are subject to the terms and conditions of the Inducement Plan and the stock option agreement pursuant to which the options were granted.

Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Calithera has an important near-term catalyst that could launch the company into a significant commercialization opportunity by mid-year 2021. The company also is running a triplet therapy trial that if successful, would be the only treatment in a $10B market.

Calithera Biosciences Poised For Long-Term Success

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced its participation at two upcoming healthcare investor conferences in November.

News for Calithera Biosciences Stock (CALA)